Functional Substitution by TAT-Utrophin in Dystrophin-Deficient Mice

James Ervasti and colleagues show that injection of a truncated form of utrophin transduced all tissues examined, integrated with members of the dystrophin complex, and reduced serum levels of creatine kinase in a mouse model of muscular dystrophy.


Introduction
Duchenne muscular dystrophy (DMD) is the most prevalent form of human muscular dystrophy and is caused by mutations in dystrophin, a 427 kDa cytoskeletal protein necessary for proper membrane stability in muscle [1]. Although recent advances in cell-, gene-, oligonucleotide-, and small molecule-based therapies have identified several promising approaches to counteract the effects of dystrophin deficiency in animal models [2][3][4][5][6][7][8][9], there are currently no effective therapies for humans with DMD. We have chosen to pursue the therapeutic potential of utrophin (Utr), an autosomal homolog of dystrophin that corrects all known phenotypes of the dystrophin-deficient mdx mouse when transgenically overexpressed to sufficient levels [10]. Our ability to express and purify scalable quantities of recombinant full-length and truncated utrophins [11], combined with the availability of cell-penetrating peptides, provides an attractive potential method for directly boosting utrophin levels in vivo.
The protein transduction domain (PTD) of the HIV-1 TAT protein has been used to effect cellular entry of TAT-fusion proteins and oligonucleotides into every tissue type examined, including muscle cells [9,12,13]. However, the ''carrying capacity'' of the TAT PTD is unknown, and the molecular weight of fulllength utrophin is over three times larger than the largest TATfusion protein described to date [12]. Therefore, we chose to compare a smaller truncated utrophin construct with full-length utrophin. Although protein truncation potentially compromises utrophin function [14], Odom et al. recently demonstrated that a virus-delivered truncated ''micro'' utrophin construct extended the lifespan and significantly improved the phenotype of mdx/utrn 2/2 mice [15]. Therefore, we sought to determine whether TATmediated full-length or micro-utrophin delivery is a viable therapeutic option for the treatment of dystrophinopathy. We expressed chimeric proteins encoding the TAT PTD fused to both full-length Utr (TAT-Utr) and DR4-21 ''micro'' Utr (TAT-mUtr) and then assessed the ability of purified full-length TAT-Utr and TAT-mUtr to prevent the dystrophic phenotype of the mdx mouse.

TAT-Utr and TAT-mUtr
The 59 coding sequence of a previously described 16 kb murine utrophin baculoviral expression construct [11] was subcloned into the plasmid pTAT (a gift from Steven Dowdy, UCSD). A Kozak consensus sequence and FLAG-epitope were engineered in-frame at the extreme 59 end of TAT-Utr before reinsertion of the modified fragment into the baculovirus expression construct. Protein expression and purification was carried out as described [11]. The construction of TAT-mUtr is detailed in Text S1. The purified proteins were sterilized for injection by passage through a 0.22 mm filter and injected into the intraperitoneal (IP) cavity of mdx mice at a concentration of 1.0 to 3.0 mg/ml.

Protein Labeling
1 mg of purified full-length TAT-Utr or TAT-mUtr was diluted to 1.0 mg/ml in PBS and labeled with IRDye 800CW -High MW Protein Labeling Kit (Li-Cor Biosciences) according to the manufacturer's instructions. The dye is stably coupled to free amines through an NHS ester reactive group. Unincorporated dye was separated by passage through a desalting spin column and the protein concentration of the labeled protein was determined. The labeled proteins were filter-sterilized prior to injection as above.

Infrared Imaging
All tissue/organ and in vivo scanning was performed on freshly killed or anesthetized mice using the Odyssey Infrared Imaging System (Li-Cor Biosciences) using both the 700 and 800 nm channels.
For tissue transduction studies, five mdx mice received two injections each, 72 h apart, of either labeled full-length TAT-Utr (20 mg/g body weight), TAT-mUtr (8.5 mg/g body weight), or equal volume injections of sterile PBS. Mice were humanely killed 72 h after the second injection and their tissues/organs were immediately dissected and scanned before freezing for subsequent protein analysis. Fluorescence intensity data from the 800 nm channel (labeled protein) was normalized first to the 700 nm channel (background) of the same tissue/organ before normalization to PBS tissue/organ.
For decay time course experiments, four mice were singly injected with equimolar amounts of either full-length TAT-Utr (two groups of four mice) or TAT-mUtr (two groups of four mice). At 3, 24, 48, and 72 h postinjection, all living mice were scanned and one mouse from each group was killed for tissue protein analyses.

Treatment
C57Bl/10ScSn-Dmd mdx /J (The Jackson Laboratory, Bar Harbor, ME) littermates were treated in parallel (unbiased by gender), and received a dose of either 5 (0.256; n = 2), 10 (0.56; n = 3), 20 (16; n = 5), 40 (26; n = 3), or 100 mg (56; n = 3) of full-length TAT-Utr/g body weight or 8.5 mg TAT-mUtr/g body weight (n = 8), while mdx littermate mice received equal volume injections of sterile PBS (n = 13). A total of six twice-weekly injections were administered over 3 wk, beginning at 18 d and culminating at 35 d of age. At 38 d of age, serum and tissue were collected for creatine kinase, Western blot, immunofluorescence, histological, and contractile analyses. For data analyses, PBS-injected animals were randomly assigned to two groups; one group (n = 7) was used for comparison to full-length TAT-Utr-treated animals while the other group (n = 6) was used for comparison to TAT-mUtr-treated animals. Animals were housed and treated in accordance with the standards set by the University of Minnesota Institutional Animal Care and Use Committee.

Protein Extracts
Tissues were dissected from freshly killed mice and snap-frozen in liquid nitrogen before subsequent analyses. For SDS-extracts, frozen tissue was pulverized and the protein extracted as previously described [11]. For samples enriched in membrane glycoproteins using wheat germ agglutinin (WGA) affinity chromatography, pulverized muscle was instead solubilized 1:10 (w:v) in 5% digitonin solubilization buffer for 1 h at 4uC. The solubilate was centrifuged at 1,000 rpm for 10 min and the supernatant then loaded onto equilibrated WGA beads (50 ml of beads per 1 ml of supernatant) and mixed end-over-end overnight at 4uC. Beads were then pelleted and washed three times in 10% digitonin wash buffer before protein was eluted in 0.3 M NAG elution buffer.

Electrophoresis/Western Blotting
For size separation, 4%-16% BN gels were loaded with 100 mg of WGA-eluted protein from TAT-mUtr-treated mdx, PBS-injected mdx, and PBS-injected mdx spiked with 0.1 mg of fluorescently labeled TAT-mUtr. The gels were run for approximately 2 h at 70 V, and then increased to 150 V for 1 h. Once the dye front had migrated halfway through the gel the cathode buffer was changed from a Coomassie G250-containing cathode buffer to a dyeless cathode buffer. After the dye front had sufficiently migrated through the native gel, the appropriate lanes were excised and loaded on top of a conventional 3%-12% gradient SDS-PAGE gel.

Histological and Morphometric Analysis
Individual muscles were dissected, coated with OCT (Tissue-Tek), and rapidly frozen in liquid nitrogen-cooled isopentane. Cryosections of 10 mm thickness were cut on a Leica CM3050 cryostat and stained with hematoxylin and eosin-phloxine. Images were collected on a Zeiss Axiovert 25 microscope and compiled into montages of entire sections in ImagePro Plus and exported to Scion Image for morphometric analyses. The percentage of centrally nucleated fibers (CNFs) and fiber diameters were determined from one muscle of each mouse, with every fiber scored for CNF analysis and ,700 fiber diameters measured per muscle section. A Student's t test was used to compare both average CNF values and average fiber diameter.

Immunofluorescence
Cryosections of 10 mm thickness were stained with primary antibodies as previously described [16]. Confocal images were obtained using an inverted Olympus Fluoview 1000 confocal microscope at the Biomedical Image Processing Lab and imported into CorelDraw 10 for figure preparation. Primary monoclonal antibodies used were identical to those described for Western blotting above.

Contractile Properties
All contractile assays are detailed in Text S1.

Serum CK Analysis
Retro-orbital bleeds were performed on anesthetized mice as previously described [16]. Data were collected in U/ml and compared by Student's t test.

Expression and Characterization of Recombinant TAT-Fusion Proteins
Full-length TAT-Utr and TAT-mUtr were expressed in baculovirus-infected Sf9 cells and purified using anti-FLAG affinity chromatography ( Figures 1A and S1A). As expected from biochemical studies that have mapped the actin-binding interface of utrophin [14], deletion of spectrin-like repeats 4-21 of the middle rod domain resulted in a 5-to 10-fold reduction in actin binding affinity for TAT-mUtr ( Figure S1B). However, the measured affinity of TAT-mUtr for actin was within the range of affinities reported for truncated dystrophin constructs that ameliorated the dystrophic phenotype in vivo [17,18].

TAT Protein Transduction and Stability
In order to assess the cellular transduction of TAT-mUtr and full-length TAT-Utr in vivo, we labeled each protein with an infrared-excitable fluorescent dye and administered two injections of labeled protein at equimolar concentrations (TAT-mUtr, 8.5 mg/g body weight; full-length TAT-Utr, 20 mg/g body weight) 72 h apart to mdx littermate mice. Mice were killed 72 h after the second injection and their tissues/organs prepared for fluorescence and protein analyses. Both infrared scanning and Western blot analysis using a FLAG epitope-specific antibody identified TAT-mUtr in every tissue/organ examined from treated mice ( Figure  S2A) while no TAT-mUtr was observed in sham PBS-injected mdx littermates. Infrared fluorescence scanning of tissues from mice injected with labeled protein revealed widespread uptake of both TAT-mUtr and full-length TAT-Utr when examined in crosssection ( Figure S2B) and at the macroscopic level in all tissues analyzed ( Figure S2C and S2D). However, the extent of transduction by TAT-mUtr and full-length TAT-Utr was tissuedependent as the fluorescence intensity of different tissues and organs varied dramatically ( Figure S2E). While some differences may be explained by the proximity of the tissue/organ to the injection site (diaphragm and several peritoneal organs showed high levels of fluorescence), it is unclear why other tissues/organs were preferentially transduced while neighboring tissues/organs were not (e.g., quadriceps versus gastrocnemius, lungs versus heart). More importantly, full-length TAT-Utr levels appeared lower than TAT-mUTR as determined by both tissue fluorescence intensity ( Figure S2E) and Western blot analysis ( Figure S2F), suggesting that TAT-mUTR either transduced tissues more effectively or was more stable in vivo.
To assess the stability of injected TAT-utrophin proteins in vivo, we administered a single injection of fluorescently tagged TAT-mUtr or full-length TAT-Utr (TAT-mUtr, 8.5 mg/g body weight; full-length TAT-Utr, 20 mg/g body weight) to mdx littermate mice and measured whole-body fluorescence intensity at 3, 24, 48, and 72 h postinjection ( Figures 1C and S3A). At each time point one animal was killed and its tissues analyzed by SDS-PAGE/Western blot to determine whether fluorescence in tissue extracts was consistent with whole-body fluorescence ( Figure 1D). Although TAT-mUtr levels decayed most rapidly in liver ( Figure 1C and 1D), the fluorescence decay in both liver and quadriceps extracts closely paralleled the whole-body fluorescence decay and approached baseline levels 72 h postinjection ( Figure 1E). Therefore, whole-body fluorescence served as a reliable readout for TAT-mUtr protein levels in vivo in subsequent stability assays. Because similar whole-body fluorescence decay profiles were observed for TAT-mUtr and full-length TAT-Utr ( Figures 1E and S3B), we concluded that the higher levels of labeled protein detected in mice injected with TAT-mUtr were due to the greater transduction efficiency of the truncated protein.
The 5-fold higher molar yield of TAT-mUtr after expression and purification (unpublished data) combined with its enhanced transduction efficiency (Figures 1 and 2) led us to focus on the therapeutic potential of TAT-mUtr. We administered twice-weekly injections based on the discovery that a fraction of injected protein remained stable for at least three days postinjection ( Figure 1D). The time frame of our injection protocol was influenced by (1) the amount of transgenic utrophin expression required to improve the mdx phenotype [10,11] and (2) evidence suggesting that utrophin up-regulation prior to the onset of muscle degeneration/ regeneration in the mdx mouse (,21 d of age) was most effective in alleviating the dystrophic phenotype [19]. Thus, mdx mice received six twice-weekly IP injections of TAT-mUtr (8.5 mg/g body weight) into mdx mice beginning at day 18 postpartum ( Figure 1F). Treated mice were killed 3 d after the sixth injection, transcardially perfused with excess PBS to clear residual injected protein from the vasculature, and assessed for several parameters of the dystrophic phenotype.

TAT-mUtr Forms a mUGC
A total of eight mdx mice (each randomly selected without bias for gender at the time of the first injection) received the sixinjection protocol while mdx littermates were injected with equal volumes of sterile PBS. To assess whether the injected TAT-mUtr achieved systemic transduction, we first analyzed several tissue extracts by Western blot and observed strong FLAG immunoreactivity corresponding to TAT-mUtr only in treated samples ( Figure 2A). The relative levels of TAT-mUtr between tissues in mice receiving six injections was greater than in mice receiving two injections, and striated muscle extracts exhibited stronger TAT-mUtr immunoreactivity after six injections compared to nonmuscle tissues (compare Figures 2A and S2A). Although the mechanism leading to this finding is unknown, it is perhaps due to differences in the inherent stability of TAT-mUtr in muscle versus nonmuscle tissues ( Figure 1D and 1E). Importantly, Western blotting with a utrophin-specific antibody showed that the amount of endogenous full-length utrophin was unchanged in tissues from mice injected with TAT-mUtr ( Figure 2B), indicating that any effect of TAT-mUtr on the dystrophic phenotype was not due to alterations in endogenous utrophin expression. To assess the intracellular localization of TAT-mUtr, we stained quadriceps muscle cryosections with primary antibodies to either utrophin or the FLAG epitope and observed intense staining along the periphery of muscle cells in treated mice, but only limited staining with a utrophin-specific antibody in PBS-injected mice ( Figure 2C). The staining pattern for TAT-mUtr was consistent with the location of dystrophin in wild-type muscle cells [1] and transgenically overexpressed utrophin in mdx tissue [10], indicating that most internalized TAT-mUtr was appropriately targeted to the subsarcolemmal space. Taken together, the Western blot and immunofluorescence data in Figure 2 demonstrate both stable systemic transduction and subcellular localization of TAT-mUtr.
Because the loss of dystrophin expression leads to a destabilization and concomitant loss of other dystrophin-glycoprotein complex (DGC) members from the muscle cell membrane [1], we examined whether TAT-mUtr restored the DGC to the sarcolemma and improved membrane stability. Immunofluorescence analyses using antibodies raised to DGC glycoproteins adystroglycan, b-dystroglycan, a-sarcoglycan, and c-sarcoglycan revealed only faint or no signal on cryosections from PBS-injected mice while each antibody probe exhibited intense staining along the periphery of muscle cells from TAT-mUtr treated mice ( Figure 3A). In addition, the intracellular constituents dystrobrevin and neuronal nitric oxide synthase (nNOS) were also localized to the cell periphery of treated muscle, suggesting that administered TAT-mUtr properly interacted with endogenous dystrophin/ utrophin binding partners ( Figure 3A). Consistent with the immunofluorescence data in Figure 3A, TAT-mUtr and all DGC components were enriched from detergent-solubilized muscle extracts by WGA-affinity chromatography while endogenous utrophin levels remained constant ( Figure 3B). These data suggest that a biochemically stable ''micro'' utrophin-glycoprotein complex (mUGC) formed complementary to the endogenous UGC in dystrophin-deficient muscle. To further test the stability of association between TAT-mUtr and the glycoprotein complex, we performed two-dimensional blue native polyacrylamide gel electrophoresis (2D BN-PAGE) on WGA-enriched muscle extracts from PBS-and TAT-mUtr-injected mice [20]. Western blots of samples from PBS-injected mice probed with antibodies to both utrophin and the FLAG epitope demonstrated that endogenous (FLAG-less) ,400 kDa utrophin comigrated with b-dystroglycan in a protein complex of ,1610 6 kDa ( Figures 3C, S4A, and S4B), evidence that 2D BN-PAGE of WGA muscle extracts can properly resolve the endogenous UGC. Importantly, Western blots of samples from TAT-mUtr-injected mice probed for Utr and the FLAG epitope showed that both endogenous (FLAG-less) Utr and FLAG-reactive TAT-mUtr comigrated with b-DG ( Figure 3C and Figure S4C). To definitively test whether the Utr/FLAG-reactive band in treated muscle extracts was aggregated TAT-mUtr that had migrated coincident with the endogenous UGC, treated muscle extracts were spiked with purified TAT-mUtr immediately prior to 2D BN-PAGE analysis. Subsequent Western blotting clearly distinguished ''free'' TAT-mUtr from TAT-mUtr complexed with b-DG ( Figure 3D). The mUGC also mitigated the membrane stability defect of mdx mice, as demonstrated by a significant reduction in serum levels of the muscle enzyme creatine kinase ( Figure 3E). In total, the data in Figure 3 demonstrate that TAT-mUtr successfully transduced skeletal muscle cells and formed a functional DGC-like mUGC that significantly improved membrane integrity in dystrophin-deficient muscle.

TAT-mUtr Improves mdx Muscle Function
Consistent with the restoration of a functional mUGC in mdx mice, gross histological examination of TAT-mUtr-treated muscles showed a marked improvement in the overall health of treated muscle. Hematoxylin-eosin-stained cryosections from TAT-mUtrtreated mouse muscle exhibited a general uniformity in cell size and appearance across several individual muscles, whereas sections from PBS-injected mice displayed extensive mononuclear cell infiltration and small regenerating fibers ( Figure 4A and 4B). We quantified the incidence of CNFs, an index of skeletal muscle cell degeneration/regeneration, and observed significantly fewer CNFs in TAT-mUtr muscles than in PBS-injected and uninjected mdx controls ( Figure 4C). The observed increase in fiber diameter in the TAT-mUtr-treated samples ( Figure 4D) was likely due to reduced numbers of the small regenerating fibers typically found in mdx muscle. All three parameters indicate that TAT-mUtr administration significantly reduced muscle cell death in the absence of dystrophin.
Dystrophin deficiency is also characterized by deficits in contractile force and a marked sensitivity to contraction-induced injury [21,22]. Extensor digitorum longus (EDL) muscles from TAT-mUtr-treated mice showed significantly improved ex vivo functional performance ( Figure 5). While mdx muscles typically exhibit a 25% reduction in specific force production compared to wild-type muscles [23], TAT-mUtr-treated mdx muscles generated comparable maximal tetanic force ( Figure 5A) but ,25% more normalized specific tetanic force ( Figure 5B) than PBS-injected mdx control muscles. In addition, mdx muscle typically loses ,75% of its force generating capacity after five lengthening (eccentric) contractions compared to ,20% for wild-type muscle [1]. TAT-mUtr treatment significantly reduced the measured force drop by nearly half, allowing treated EDLs to maintain higher forcegenerating capability after each of five eccentric contractions compared to PBS-injected controls ( Figure 5C). These results indicate that IP administration of TAT-mUtr significantly improved the contractile performance of dystrophin-deficient mdx muscle.
To test the efficacy of full-length TAT-Utr, we treated six mdx littermate mice as above, injecting full-length TAT-Utr at both the equivalent (16) and varied molar ratios (0.256, 0.56, 26, and 56) to the dosage described for TAT-mUtr. Like TAT-mUtr, full-length TAT-Utr transduced all tissues examined at the 16dosage ( Figure  S4B and S5A) and was properly localized to the periphery of muscle cells ( Figure S5C). Similar to TAT-mUtr, full-length TAT-Utr significantly reduced muscle degeneration/regeneration ( Figure S6A-S6D) and improved membrane stability ( Figure  S6E). However, muscle contractile performance was not significantly improved by full-length TAT-Utr even when tested at 5fold higher dosages ( Figure S6F). We conclude that the enhanced protein transduction gained by reducing the molecular weight of utrophin overcomes any loss of TAT-mUtr's biological function and propose TAT-mUtr as a potential direct protein replacement therapy for dystrophinopathies.

Discussion
Our experiments are, to our knowledge, the first to demonstrate the feasibility and efficacy of direct protein replacement to combat the effects of dystrophin deficiency in mdx mice, an established model of Duchenne muscular dystrophy in humans. IP injections of the cell-penetrating TAT-mUtr restored proper membrane targeting of dystrophin protein complex members, stabilized muscle membrane integrity, attenuated histological hallmarks of dystrophy, and conferred functional benefits to treated muscle.
The initial studies in which dystrophin deficiency was corrected by a reintroduction of either dystrophin [24] or utrophin expression [10] caused widespread excitement that an effective treatment would soon be realized. Despite consistent progress over the intervening years, obstacles to gene-, oligonucleotide-, or small molecule-based approaches to up-regulate the relevant proteins still exist and have thus far prevented effective therapeutic intervention in human patients. Our development of TAT-mUtr and demonstration of its beneficial effects on dystrophic muscleall without affecting endogenous utrophin levels or functionintroduces a novel therapeutic approach that we predict would work complementarily and synergistically with other strategies, in particular those aimed at up-regulating endogenous utrophin expression [25,26]. The beneficial effects of combining such therapies should theoretically be additive with the prediction that the cumulative increase in utrophin levels would be sufficient to substantially prevent or delay the phenotypes associated with dystrophin deficiency.
Our proof-of-concept results offer the first evidence, as far as we know, that an exogenous protein replacement-based therapy holds promise for the treatment of dystrophinopathies. Besides the obvious example of Duchenne muscular dystrophy, we are intrigued by the possibility that TAT-mUtr may also be able to compensate for the loss of dystrophin in genetic or acute forms of cardiomyopathy [27,28]. Actin cosedimentation assays were performed as previously described [1], except the concentration of utrophin was held constant while the concentration of actin was varied. The TAT domain did not interfere with actin binding in the full-length TAT-Utr construct (0.22 versus 0.11 mM), while deletion of spectrin-like repeats 4-21 caused a 5-to 10-fold reduction in actin binding affinity for TAT-mUtr (0.22 versus 1.14 mM). n$3 for each protein.   Editors' Summary Background. Muscular dystrophies are genetic (inherited) diseases in which the body's muscles gradually weaken and degenerate. The commonest and most severe muscular dystrophy-Duchenne muscular dystrophy-affects 1 in 3,500 boys (girls can be carriers of the disease but rarely have any symptoms). At birth, these boys seem normal but the symptoms of their disease begin to appear in early childhood. Affected children may initially have difficulty walking or find it to hard to sit or stand independently. As they age, their muscle strength progressively declines and most affected boys are confined to a wheelchair by the time they are 12 years old. The muscles involved in breathing also weaken and the heart muscle becomes enlarged. Few boys with Duchenne muscular dystrophy live beyond their early 20 s, usually dying from breathing or heart problems. At present there is no cure for Duchenne muscular dystrophy. However, physical therapy and treatment with steroids can prolong the ability of patients to walk, and assisted ventilation can help with their breathing.

Supporting Information
Why Was This Study Done? In all muscular dystrophies, one of the proteins needed to build and maintain healthy muscles is missing or nonfunctional because of a genetic change (mutation). In Duchenne muscular dystrophy the mutation is in dystrophin, a protein that is involved in the formation of the dystrophin-glycoprotein complex. This complex normally sits in the membranes that surround muscle fibers and protects these membranes from damage during muscle contraction. Consequently, in Duchenne muscular dystrophy, the muscle fiber membranes become damaged and eventually the muscle fibers die. Thus, if functional dystrophin could be introduced into the muscles of patients with Duchenne muscular dystrophy, it might be possible to reduce their symptoms and prolong their lives. Indeed, the effects of dystrophin deficiency in the dystrophin-deficient mdx mouse can be reduced by the introduction of an artificial gene that expresses dystrophin or the closely related protein utrophin. Unfortunately, this gene therapy approach has not yet been effectively demonstrated in humans. In this study, therefore, the researchers investigate whether utrophin protein can be introduced directly into dystrophin-deficient mouse muscles by exposing the muscle cells to utrophin fused to the protein transduction domain of the HIV-1 TAT protein. Most proteins will not cross cell membranes, but proteins fused to this cellpenetrating domain readily enter many cell types, including muscle cells.
What Did the Researchers Do and Find? The researchers injected full-length utrophin fused to the TAT protein transduction domain (TAT-Utr) and a short, ''micro'' version of utrophin fused to the same domain (TAT-mUtr) into the abdomens of mdx mice and looked to see where the proteins ended up. After two injections, both proteins were present in a wide range of tissues and organs, including several types of muscle. However, the levels of TAT-Utr were much lower than those of TAT-mUtr. Next, the researchers injected another group of mdx mice with TAT-mUtr six times over three weeks. Again, TAT-mUtr was present in all the tissues that the researchers examined. Furthermore, mUtrglycoprotein complexes formed in the TAT-mUtr injected mdx mice and the membrane integrity and overall health of the dystrophin-deficient muscles of the mdx mice improved compared to mdx mice treated with saline. Finally, the researchers report, TAT-mUtr injections greatly improved the contractile performance of the muscles of the mdx mice.
What Do These Findings Mean? These findings provide the first demonstration that injection of TAT-utrophin protein fusions may provide a way to treat muscular dystrophies caused by the loss of dystrophin. However, although this direct protein-replacement therapy looks hopeful, approaches that work in animals do not necessarily work in people. In particular, for this approach to work in patients with muscular dystrophy, it would be necessary to give frequent, high-dose injections of the TAT-mUtr fusion protein, a process that could eventually trigger a deleterious immune response. Nevertheless, the researchers suggest that by combining this novel approach with other approaches that also increase utrophin expression, it might be possible to prevent or delay the development of the symptoms of Duchenne muscular dystrophy.